Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
Status:
Withdrawn
Trial end date:
2021-05-04
Target enrollment:
Participant gender:
Summary
This is an open label, single institution, dose-escalation phase 1 study designed to assess
the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde
Venous Infusion (PRVI) using Pressure Enabled Drug Delivery (PEDD) technology. Oxaliplatin
PEDD-PRVI is administered with systemic FOLFIRI followed by FOLFIRINOX therapy for the
treatment of patients with unresectable or metastatic pancreatic adenocarcinoma.